About: High frequency of SARS-CoV-2 RNAemia and association with severe disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: High frequency of SARS-CoV-2 RNAemia and association with severe disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	High frequency of SARS-CoV-2 RNAemia and association with severe disease
Creator	Hogan, Catherine Huang, Pinsky, Benjamin Sahoo, Malaya Garamani, Natasha Gombar, Saurabh Stevens, Bryan Zehnder, James Chunhong, Kurzer, Jason Murugesan, Kanagavel Pinsky, Yamamoto, Fiona
source	MedRxiv
abstract	Background: Detection of SARS-CoV-2 RNA in the blood, also known as RNAemia, has been reported, but its prognostic implications are not well understood. This study aimed to determine the frequency of SARS-CoV-2 RNA in plasma and its association with the clinical severity of COVID-19. Methods: An analytical cross-sectional study was performed in a single-center tertiary care institution in northern California and included consecutive inpatients and outpatients with COVID-19 confirmed by detection of SARS-CoV-2 RNA in nasopharyngeal swab specimens. The prevalence of SARS CoV-2 RNAemia and the strength of its association with clinical severity variables were examined and included the need for transfer to an intensive care unit (ICU), mechanical ventilation and 30-day all-cause mortality. Results: Paired nasopharyngeal and plasma samples were included from 85 patients. The overall median age was 55 years, and individuals with RNAemia were older than those with undetectable SARS-CoV-2 RNA in plasma (63 vs 50 years; p=0.001). Comorbidities were frequent including obesity (37.7%), hypertension (30.6%) and diabetes mellitus (22.4%). RNAemia was detected in a total of 28/85 (32.9%) individual patients, including 22/28 (78.6%) who required hospital admission. RNAemia was detected more frequently in individuals who developed severe disease including the need for ICU transfer (32.1% vs 14.0%; p=0.05), mechanical ventilation (21.4% vs 3.5%; p=0.01) and 30-day all-cause mortality (14.3% vs 0%; p=0.01). No association was detected between RNAemia and estimated levels of viral RNA in the nasopharynx. An additional 121 plasma samples from 28 individuals with RNAemia were assessed longitudinally, and RNA was detected for a maximum duration of 10 days. Conclusion: This study demonstrated a high proportion of SARS-CoV-2 RNAemia, and an association between RNAemia and clinical severity suggesting the potential utility of plasma viral testing as a prognostic indicator for COVID-19.
has issue date	2020-05-01(xsd:dateTime)
bibo:doi	10.1101/2020.04.26.20080101
has license	medrxiv
sha1sum (hex)	d5ad4166689e169c67c4dca08d54dba1ec9a30f6
schema:url	https://doi.org/10.1101/2020.04.26.20080101
resource representing a document's title	High frequency of SARS-CoV-2 RNAemia and association with severe disease
resource representing a document's body	covid:d5ad4166689e169c67c4dca08d54dba1ec9a30f6#body_text
is schema:about of	named entity 'determine' named entity 'blood' named entity 'variables' named entity 'institution' named entity 'SINGLE' named entity 'INCLUDED' named entity 'intensive care unit (ICU)' named entity 'day' named entity 'transfer' named entity 'performed' named entity 'SARS-CoV-2' named entity 'analytical' named entity 'SARS-CoV-2' named entity 'RNA' named entity 'plasma' named entity 'SARS-CoV-2' named entity 'peer review' named entity 'nasopharyngeal' named entity 'copyright holder' named entity 'reverse transcriptase' named entity 'viral RNA' named entity 'coronavirus disease 2019' named entity 'RNA' named entity 'preprint' named entity 'copyright holder' named entity 'preprint' named entity 'polymerase' named entity 'peer review' named entity 'medRxiv' named entity 'preprint' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'preprint' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'northern California' named entity 'SARS CoV' named entity 'RNA' named entity 'nasopharyngeal swab' named entity 'preprint' named entity 'medRxiv' named entity 'RNA' named entity 'severe acute respiratory syndrome coronavirus' named entity 'medRxiv' named entity 'medRxiv' named entity 'medRxiv' named entity 'serum' named entity 'peer review' named entity 'viral RNA' named entity 'copyright holder' named entity 'preprint' named entity 'peer review' named entity 'peer review' named entity 'all-cause mortality' named entity 'prognostic' named entity 'High frequency' covid:arg/d5ad4166689e169c67c4dca08d54dba1ec9a30f6 named entity 'intensive care unit' named entity 'cross-sectional study' named entity 'mechanical ventilation' named entity 'SARS-CoV-2' named entity 'REPORTED' named entity 'INTENSIVE CARE UNIT' named entity 'NOT WELL' named entity 'HIGH FREQUENCY' named entity 'SARS-COV-2' named entity 'nasopharyngeal swab' named entity 'tertiary care' named entity 'ICU' named entity 'SARS-CoV-2' named entity 'RNA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software